News > Press Releases

European scientists receive funding from Seventh EU Framework Programme to develop novel therapies for inflammation-associated cancer.

Jun 11, 2009

A network of scientists led by the Foundation of Research & Technology - Hellas (FORTH), Greece, have been awarded a grant from the European Commission Seventh Framework Program, aiming to increase our understanding of how chronic inflammation in the body can lead to cancer. It is anticipated that this research program, code-named INFLA-CARE, for Inflammation and Cancer Research in Europe, will also lead to the development of novel approaches for the treatment and improved management of inflammation-associated malignancies, such as liver and colon cancer.

Dr Aristides Eliopoulos, who is the co-ordinator of the INFLA-CARE programme, commented: "The INFLA-CARE researchers are delighted to have received funding for this research programme. It provides us with a unique opportunity to bring together world-class experts in cancer biology, medicine and biotechnology, all working together with the aim of advancing our knowledge about how cancer develops. The ultimate goal of the project is to translate the scientific advances made in the laboratory into novel treatments that enable us to tackle cancer at a very early stage. We hope to make a real difference in the prevention and treatment of malignant disease."

INFLA-CARE integrates the core skills and expertise of researchers from a total of twenty one Institutions in Europe and Israel and is supported with 12 million euro from the European Commission for a period of 4 years.

INFLA-CARE contact:
Aristides Eliopoulos, PhD
Associate Professor
Institute of Molecular Biology & Biotechnology
Foundation for Research & Technology - Hellas
Heraklion, Crete, Greece
Tel/Fax: +30 2810 394565